OBJECTIVES: Cross-talk between organ-specific extracellular matrix (ECM) and stem cells is often assumed but has not been directly demonstrated. We developed a protocol for the preparation of human cardiac ECM (cECM) and studied whether cECM has effects on pluripotent stem cell differentiation that may be useful for future cardiac regeneration strategies in patients with end-stage heart failure.
INTRODUCTION
The suitability of somatic progenitor cell products for myocardial repair has been evaluated in various clinical trials. Although there have been encouraging data from pilot studies using cells from bone marrow, adipose tissue or the heart, there is now consensus that these cell types cannot recreate contractile myocardium in relevant quantity. So far, reproducible cardiomyogenesis requires the use of pluripotent stem cells or genetic reprogramming, but both strategies are not yet ready for clinical testing. One of the many open questions concerns the interactions between stem cells and organ-specific extracellular matrix (ECM). In cardiac tissue engineering, decellularized heart tissue has been proposed as a scaffold for the development of contractile cell patches or as a transplantable carrier for cells with regenerative potential [1, 2] . While biological tissue scaffolds were shown to provide the ideal three-dimensional architecture for recreation of solid organs [1, 2] , the biologic interactions between ECM and 'regenerating' cells remain poorly understood. In the context of experimental cardiac cell therapies, these interactions could either contribute to therapeutic failure or may have beneficial effects on certain types of transplanted cells. For instance, it is often assumed that ECM provides cues for organ-specific differentiation of stem cells, but the existence and nature of such signals has rarely been demonstrated [3] . We have recently developed a protocol for decellularization of human myocardium that preserves all major ECM components (cECM) [4] , and now tested the hypothesis that cECM can influence the behaviour of pluripotent stem cells, possibly directing their differentiation towards a cardiomyocyte-like phenotype.
METHODS

Decellularization of human myocardial tissue
The study protocol conforms to the ethical principles outlined in the Declaration of Helsinki. For this study, LV myocardium from 3 patients with dilated cardiomyopathy (DCM) who underwent heart transplantation at DHZB (Deutsches Herzzentrum Berlin) was used. All patients provided informed consent for the use of the tissue for research purposes, and the process of tissue collection was approved by the Institutional Review Board and ethics committee of Charité Medical University (EA4/028/12). Two patients were male and one was female (mean age 39 ± 7 years), uniformly had non-ischaemic DCM with a negative history of myocardial infarction and were in New York Heart Association Class IV with left ventricular ejection fraction (LVEF) by echocardiography of <25%. Care was taken to use only myocardium that had no relevant fibrosis by gross morphology and microscopy. cECM from all 3 patients was used for the various experiments and no attempt was made to stratify the outcome data according to individual patient characteristics. The myocardium was decellularized using a three-step protocol that we have previously evaluated in detail [4] . Briefly, 0.3-mm thick tissue sections were prepared using a cryostat (CM 3050S, Leica, Wetzlar, Germany), and were then decellularized by incubation in lysis buffer for 2 h (10 mM Tris, 0.1% ethylenediaminetetraacetic acid, pH 7.4), 0.5% sodium dodecyl sulphate (SDS) for 6 h and serum for 3 h, followed by washing steps in phosphate buffered saline (PBS) with penicillin/streptomycin and nystatin (100 U/ml each). Samples were stored in sterile containers without further preservation procedures at 4°C before recellularization.
Cell culture
Because differences in regenerative potential between induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) cannot be excluded, we included both cell types in this study. Therefore, we chose to study murine cells, which are ethically less controversial. Murine AT25 iPSCs [5] and α-PIG ESCs [6] were cultured on a feeder layer of irradiated mouse embryonic fibroblasts (CellSystems, Troisdorf, Germany) in medium consisting of high glucose Dulbecco's modified Eagle medium (DMEM) (no. 31966, Life Technologies, Darmstadt, Germany) with 15% foetal bovine serum (FBS), 0.1 mM minimum essential medium (MEM) nonessential amino acids, 50 μM 2-mercaptoethanol and 1 U/μl leukaemia inhibitory factor (LIF) to maintain the undifferentiated stem cell state. Murine bone-marrow mesenchymal stem cells (MSCs) have been characterized in detail as described elsewhere [7] . They were cultured in murine MSC medium (PAN, Aidenbach, Germany) with 2.5 ng/ml fibroblast growth factor and 100 U/ml penicillin/streptomycin. Cells had been subcultured nine times (Passage 9) when used for recellularization.
Recellularization
cECM was recellularized in 96-well plates as described [4] . Scaffolds were fitted into wells, and cell suspensions were pipetted onto the cECM or into empty control wells, and cultivated at 37°C, 5% CO 2 and 21% O 2 in a humidified incubator. The medium used after recellularization was generally the same as used for regular cell culture. For iPSCs and ESCs, penicillin/streptomycin was added and LIF was withdrawn after recellularization to allow for spontaneous differentiation.
Viability assay
Cell viability was analysed using the CellTiter 96 AQueous nonRadioactive Cell Proliferation Assay (Promega, Mannheim, Germany), a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Briefly, the medium in 96-well plates containing the samples was replaced by 100 μl PBS with 5% glucose and 20 μl MTS plus phenazine methosulfate reagent mixture. Samples were incubated for 4 h and the colour reaction in the presence of viable cells was analysed by spectrophotometry at 490 nm. Wells with cells on cECM were compared with wells containing only cells. Blank values from wells without cells were subtracted from the results.
Caspase 3/7 activity assay
Activity of Caspase 3/7 in recellularized samples and cell controls was analysed by Caspase-Glo 3/7 Assay (Promega). 20 000 cells were seeded in wells of a 96-well plate with or without cECM and allowed to attach for 1 day. For the test, medium in 96-well plates was replaced with 50 μl PBS with 5% glucose per well at room temperature (RT). Fifty microlitres Caspase-Glo reagent were added and the plate was incubated at RT for 1 h. Afterwards, 80 μl from each well were transferred to a white-walled plate, to avoid influence of the cECM on plate readings. Luminescence as an indicator of relative Caspase 3/7 activity was measured in a Mithras LB 940 plate reader (Berthold Technologies, Bad Wildbad, Germany), and blank values from empty wells were subtracted.
Histology and immunohistochemistry
Samples were fixed with 4% buffered paraformaldehyde, sequentially embedded in 15 and 30% (wt/vol) sucrose in PBS, Tissue-Tek optimal cutting temperature compound, and flash-frozen on dry ice/ethanol before they were sectioned with a cryostat. Sections of 10 μm thickness were placed onto microscope slides. Haematoxylin and eosin (H&E) staining was carried out according to standard procedures using Mayer's H&E G solution (Carl Roth, Karlsruhe, Germany), and Masson's trichrome staining was performed using the Accustain Trichrome Stain kit (Sigma-Aldrich, Taufkirchen, Germany). It included incubations in Bouin's solution, Weigert's iron haematoxylin, Biebrich scarlet-acid fuchsin, a mixture of phosphomolybdic and phosphotungstic acid and aniline blue. Masson's trichrome staining allows for a distinction between cellular and extracellular material, as it results in purple nuclei, red cytoplasm and blue connective tissue. Samples for immunohistochemistry were incubated for 1 h in blocking buffer consisting of PBS with 5% goat serum and 0.1% Triton X-100, before proceeding to primary antibody incubation. All antibodies were purchased from Abcam (Cambridge, UK), diluted in blocking buffer and incubated with the samples at RT for 1 h or 4°C overnight. The following antibodies were used: desmin (1:200, ab8592), laminin (1:250, ab11575), fibronectin (1:200, ab23750), cardiac troponin T (cTnT, cardiac-specific, 1:300, ab8295) or heavy-chain cardiac myosin (MHC, 1:200, ab15). Samples were washed with PBS and incubated with biotinylated secondary antibody (VEC-BA-9200, Biozol, Eching, Germany, 1:500 in blocking buffer) for 1 h at RT. This step was followed by washing and incubation in horseradish peroxidase streptavidin (Biozol, 1:400 in PBS) for 50 min, washing, and incubation in diaminobenzidine (1.5 mg in 3 ml PBS with 2 μl 30% H 2 O 2 ) for 2-3 min. The reaction was stopped with distilled water. To stain cell nuclei, slides were additionally incubated in Mayer's haematoxylin (Carl Roth) for 7 min. After a final washing step, slides were dehydrated by graded alcohol series, cleared with Roti-Histol (Carl Roth), sealed and analysed under a light microscope.
Scanning electron microscopy
Scanning electron microscopy was performed as described elsewhere [4] , using glutaraldehyde fixation, dehydration by graded acetone series and critical point drying with CO 2 (CPD 030 Critical Point Dryer, BalTec, Pfäfficon, Switzerland). Samples were sputter coated with gold and analysed with a Hitachi S-2700 scanning electron microscope.
Gene expression studies by quantitative real-time polymerase chain reaction Four groups of samples were prepared: (i) Murine iPSCs, ESCs or MSCs seeded on cECM in a 96-well plate (ii) iPSCs/ESCs/MSCs seeded in empty wells. (iii) iPSCs/ESCs seeded in wells coated with 50 μl Geltrex (growth-factor reduced, Life Technologies). Cells from Groups (i-iii) were seeded at a density of 500 000 cells/cm² and cultured for 20 days in their standard medium without LIF. To avoid cell death due to overconfluency in the 96-well plates, cells and matrices were transferred to 6-well plates during the culture period, which was coated with 450 μl Geltrex/well for Group (iii). (iv) iPSCs/ESCs cultured in a Matrigel sandwich similar to the protocol recently described by Zhang et al. [3] . Six-well plates were coated with 33 μg/ml Matrigel (growth-factor reduced, Sigma-Aldrich). For this purpose, 41.7 μl Matrigel solution were mixed with 10 ml cold serum-free medium and 2.5 ml of the solution were added per well. After gelling, the serum-free medium was removed and murine iPSCs and ESCs were plated onto the coated plates at a density of 100 000 cells/cm² in their standard medium without LIF. When cells were 80-90% confluent, a layer of Matrigel was placed on top of the cells (same concentration as initial coating). Another Matrigel overlay was performed at 100% confluency. The protocol for the Matrigel sandwich was derived from the publication of Zhang et al. [3] where it favoured epithelial-to-mesenchymal transition in human pluripotent stem cells, one of the steps involved in cardiomyogenesis. Cells were also cultured for a total of 20 days. Total ribonucleic acid (RNA) was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and remaining deoxyribonucleic acid (DNA) was removed with the TURBO DNA-free kit (Life Technologies). RNA quality was checked via gel electrophoresis on a 1% agarose gel and by spectrophotometry on a NanoDrop ND-1000 spectrometer (Peqlab, Erlangen, Germany), which also served to determine RNA concentration. For reverse transcription, we used the SuperScript III first-Strand Synthesis System (Life Technologies). Quantitative rtPCR was performed in the Mastercycler ep gradient realplex 2 (Eppendorf, Hamburg, Germany) using the Power Sybr Green PCR Master Mix (Life Technologies) and gene-specific primers, which are detailed in Table 1 . The cycling programme consisted of 10 min at 95°C and 40 cycles of 95°Cfor 15 s and 60°C for 1 min. Expression values were calculated according to the Pfaffl method [16] , and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was used for normalization.
Statistical analysis
Data are expressed as mean ± standard error (SEM). For intergroup comparison of the MTS and Caspase activity data, which 
CCAACACCAACCTGTCCAAGT AGAGGTTATTCCTCGTCGTGCAT Nkx2.5 [10] CCAGAACCGTCGCTACAAGT GGGTAGGCGTTGTAGCCATA Tnnt2 [11] GCCAAAGATGCTGAAGAAGG TTCTCGAAGTGAGCCTCGAT Mef2c [12] ATTTGGGAACTGAGCTGTGC CGCTCATCCATTATCCTCGT Gata4 [12] AATGCCTGTGGCCTCTATCA CTGGTTTGAATCCCCTCCTT Vwf [13] CCCCACGGATGGCTAGGAATT GAGGCGGATCTGTTTGAGGCT VE-cadherin [13] ATTGAGACAGACCCCAAACG TTCTGGTTTTCTGGCAGCTT Ncam1 [14] ACGGGAACTCCATCAAGGTGAACCTGA TAGACTTCATACTCTGCGTTCCAGT Sox17 [15] GGCACAGCAGAACCCAGA CCAAGACTTGCCTAGCAT Most primers were taken from previously published articles. The source is indicated in brackets. Primers were validated by determining their efficiency in our settings.
were obtained on different days, repeated-measures analysis of variance (rANOVA) was applied. This test allows for statements about the influence of time, group and the interaction between these two factors. Only the P-values for group comparisons (Groups: +cECM and −cECM) were of interest for this study and are shown in the graphs. Gene expression data were compared by one-way ANOVA with Games-Howell post hoc tests. A P-value of ≤0.05 was considered significant. Tests were carried out using the IBM SPSS Statistics 20 software (IBM, Armonk, NY, USA).
RESULTS
Human cardiac extracellular matrix
The decellularization processes yielded human myocardial ECM that had changed to a white colour, consisted of a network of ECM fibres and was free from cellular residues (Fig. 1A) . Cellular proteins like desmin were removed, while laminin and fibronectin as examples for ECM proteins were still present in the cECM (Fig. 1B) . A more detailed analysis of cECM has been provided before, showing that all major ECM constituents were at least partially preserved [4] .
Attachment and infiltration of stem cells
Both ESCs and iPSCs attached to the human cECM and proliferated on the surface of the scaffold as well as infiltrating its inner pores. Masson's trichrome staining showed dense cell layers on the cECM surface, and individual cells that had migrated within the scaffold (Fig. 1C) . Electron microscopy provides an impression of cell morphology on the cECM surface (Fig. 1D ). Ten days after recellularization, pluripotent stem cells displayed the typical spheroid morphology with intact cell membrane and, at that stage, limited intercellular connections.
Cell proliferation on cardiac extracellular matrix scaffolds
Cells were viable for a test period of 10 days, as shown by MTS assays on days 2, 4, 6, 8 and 10 after recellularization or plating. Proliferation rate, that is the increase in MTS conversion rate over time, depended on the initial seeding density and was highest for a low density of 5000 cells/cm 2 (Fig. 2) . Statistical comparison of the entire 10-day data sets for the −cECM and the +cECM group showed that ESCs and their progeny proliferated significantly better on cECM than in standard culture. iPSC proliferation rate was not influenced by cECM.
Lower activity of apoptotic markers in cells cultured with cardiac extracellular matrix
On Days 1-3 after seeding, Caspase 3/7 activity was lower in both ESCs and iPSCs in contact with cECM compared with standard culture (Fig. 3A) . At that stage, the disparity in caspase activity was not due to a different cell number, because MTS activity measured at the same time points was similar between the groups (Fig. 3B) .
Messenger RNA expression
To assess whether contact with cECM or other ECM preparations directs stem cells differentiation towards a cardiomyocyte-like phenotype, we studied the upregulation of various typical stem cell and cardiomyocyte genes and proteins. The quantitative rtPCR data are shown in Fig. 4 and P-values are indicated in Table 2 . We analysed expression of the early cardiac markers NK2 homeobox 5 (Nkx2.5), myocyte enhancer factor 2C (Mef2c) and GATA-binding protein 4 (Gata4), the late cardiomyocytes markers cardiac alpha myosin heavy polypeptide 6 (Myh6) and cardiac troponin T2 (Tnnt2), the endothelial markers vascular endothelial cadherin (VE-cadherin) and von Willebrand factor (Vwf ), the pluripotency markers octamer-binding transcription factor 4 (Oct4) and sex-determining region Y box 17 (Sox2), as well as endodermal marker sex determining region Y box 17 (Sox17) and ectodermal marker neural cell adhesion molecule 1 (Ncam1). ESCs cultured on cECM displayed upregulation of early (Nkx2.5, Mef2c, Gata4) and mature (Myh6, Tnnt2) cardiomyocyte markers as well as transcription of endothelial (VE-cadherin, Vwf ), endodermal (Sox17) and ectodermal (Ncam1) genes. Without any ECM support, however, Myh6, Tnnt2, Nkx2.5 and Gata4 mRNA was expressed at much lower levels, while VE-cadherin, Vwf and Ncam1 levels were similar to those on cECM. Interestingly, neither Myh6, Tnnt2, Nkx2.5 nor Mef2c expression was induced when ESCs differentiated in contact with Matrigel or Geltrex, while Vwf and Sox17 transcription was clearly activated by both commercial ECM preparations and VE-cadherin expression by Matrigel. The only cardiomyocyte-specific gene that was induced by Matrigel or Geltrex was Gata4. The behaviour of iPSCs in contact with different matrices was not identical to that of ESCs. Matrigel seemed to preserve iPSC pluripotency as evidenced by sustained expression of Oct4 and Sox2. VE-cadherin and Sox17 mRNA was detected in much lower quantities than in ESCs, while Vwf induction was most pronounced in iPSCs on the Matrigel sandwich. Again, cECM induced upregulation of Myh6, Tnnt2 and Nkx2.5, but Gata4 and Mef2c mRNA expression was negligible in iPSCs on cECM. Myh6 and Nkx2.5 were also induced by Geltrex, and Matrigel selectively induced Mef2c as the only cardiomyocyte marker. As expected, pluripotency genes were not expressed in MSCs, and only Ncam1 and Mef2c were detectable after culture on cECM.
Protein expression
As indicated in Fig. 5 , cardiac troponin T and myosin heavy-chain protein were expressed in both ESCs and iPSCs that were allowed to differentiate in contact with cECM. MSCs, however, remained negative for cTnT and MHC.
DISCUSSION
We analysed the behaviour of pluripotent stem cells in contact with human cECM. Overall, stem cell viability and activity was supported by cECM, and, when iPSCs or ESCs underwent spontaneous differentiation, there was evidence of favoured cardiomyocyte lineage commitment by mRNA and protein expression of cardiac-specific genes. Clearly, cECM contact did not result in uniform development of fully differentiated beating cardiomyocytes, but our findings support the notion of tissue-specific interactions between cECM and stem cells, and suggest that cECM may be a useful tool in the development of clinical stem cell-based therapies.
The impact of artificial or biological scaffolds on stem cell behaviour has recently become a major research topic in the context of regenerative medicine [17] . Micro-or nanostructured polymers have been shown to direct stem cell differentiation, and the ultimate goal is the creation of a standardized culture environment that forces pluripotent cells to uniformly differentiate into a given target phenotype, without the need for further pharmacological or genetic manipulation. However, artificial scaffolds may not be able to mimic the complex architecture of a biological matrix. In the cardiovascular system, this has been acknowledged for connective tissue-based 'passive' structures such as blood vessels or heart valves [18, 19] , and should be even more relevant regarding the regeneration or in vitro creation of parenchymal tissues with an active biological function. There are concepts for the in vitro creation of myocardium based on artificial scaffolds, but their design is much simplified compared with biological matrix. Proof-of-concept regarding the suitability of cardiac matrix to serve as a scaffold for myocardial tissue engineering has been provided recently, but so far this work is largely based on ECM from animal hearts and utilizes mature, neonatal cardiac or mesenchymal stem cells for repopulation [2, 20] . Using human cECM and murine cells, we found that stem cell proliferation is supported and, at least for ESCs, higher than that in standard culture conditions. Moreover, activation of pro-apoptotic effector Caspases 3 and 7, which indicate a late stage in the programmed cell death cascade [21] , is suppressed. When the cells' connection to the ECM is disrupted, anoikis, programmed cell death caused by the loss of cell-matrix interactions occurs [22] , and contact with cECM may prevent this phenomenon.
Both ESCs and iPSCs are pluripotent stem cells that, in principle, can differentiate into cells from all three germ layers, and they do so spontaneously as soon as cellular feeder layers and leukaemia inhibitory factor are withdrawn. Spontaneously beating, functioning cardiomyocytes can be detected in stem cell cultures allowed to differentiate, and it is therefore not surprising that cardiomyogenesisrelevant genes are found to be expressed in some cells. The novelty of our findings lies in the quantitative comparison with other matrix preparations. Without any kind of matrix support, ESCs showed comparatively high ectodermal and endothelial marker expression, but very little early or mature cardiac gene expression, while iPSCs displayed a rather unspecific behaviour without matrix support. As has been described before, we found that Matrigel helps preserve pluripotency in iPSCs [23] , but, at least without using additional specific media, not in ESCs. Zhang et al. recently used a Matrigel-based sandwich technique that seemed to enhance epithelial-mesenchymal Figure 4 : rtPCR analysis of murine iPSC, ESC and MSC gene expression after a 20-day culture period on and within cardiac ECM versus cells cultured in normal cell culture plates. ESCs and iPSCs were additionally cultured on Geltrex or in a Matrigel sandwich, n = 6. Culturing on cardiac ECM led to significantly increased expression of mature cardiac markers in pluripotent cells, while pluripotency markers and markers for other cell lineages did not differ significantly. Culture on Geltrex or in a Matrigel sandwich showed gene expression changes, but no specific effect on cardiac differentiation. Most markers were not detected in MSCs. N.D.: not detected. transition in human iPSCs, which ultimately led to cardiomyocytic differentiation when combined with a specific combination of growth factors [3] . We found that Matrigel helps preserve iPSC pluripotency rather than emitting cardiomyogenic signals, which may ultimately have rendered more cells susceptible to the growth-factor effects. However, our results are not directly comparable, as we used murine instead of human cells and did not add growth factors. ESC pluripotency genes however, were not higher expressed on Matrigel, than in culture without any ECM. Endodermal as well as endothelial genes (VE-cadherin, Vwf) were upregulated, but there was exceedingly little expression of early or mature cardiomyocyte markers, with the exception of Gata4. A similar pattern was found with Geltrex. As expected, differentiating stem cells expressed endodermal (Sox17) and ectodermal (Ncam1) markers, as well as a range of mesoderm-derived cardiomyocyte-and endothelial cell-specific genes. In contact with cECM, however, Nkx2.5, a gene associated with early cardiac development, as well as the mature cardiomyocyte markers Myh6 (encoding for α-Myosin heavy chain) and Tnnt2 (encoding for cardiac troponin T) were clearly expressed at higher levels than in any other setting, and we could also confirm expression of cTnT and MHC protein by immunohistochemistry. The iPSC-derived progeny may have matured faster than that of ESCs, because both Mef2c and Gata4 expression was very low, while Myh6 and Tnnt2 were high in the presence of cECM.
The plasticity of somatic stem cells has long been controversial. While several studies demonstrated cardiomyocyte differentiation of MSCs in response to demethylation or growth factors, there is now consensus that MSCs are not suitable for cardiomyocyte generation, except by means of genetic reprogramming. Our data confirm that MSCs have very little, if any plasticity, with the exception of Mef2c expression in contact with cECM. Transcriptional upregulation of Mef2c in MSCs has been shown in response to several biological and physical stimuli [24] , but, given that alternative splicing plays a role in its control of cardiomyocyte development, its expression alone is not indicative of guided differentiation. Godier-Furnemont et al. [1] developed a composite scaffold consisting of human cECM, fibrin glue, and stromal precursor antigen 3 (Stro3) enriched MSCs (mesenchymal progenitor cells, MPCs), which they grafted on infarcted rat hearts. In their experiments, combined exposure to transforming growth factor-beta (TGF-β) and fibrin mainly led to upregulation of angiogenesis markers. While they did not specifically describe the impact of cECM alone, it agrees with our finding that cECM alone does not have much of an influence on MSC behaviour, so that additional manipulation is required.
Limitations of the study
Cardiac ECM composition may be variable and can change especially in response to disease. While our study design sufficed to demonstrate the influence of ECM on stem cell differentiation in principle, better defined and more homogenous ECM preparations would be needed for therapeutic applications. It is also well-known that factors such as gender, age and disease affect somatic stem cell differentiation [25] . We sought to account for this by using MSCs from healthy young mice, but cannot completely exclude interference with our results. The pluripotent cells we used should, to the best of our knowledge, not be affected. The cECM was not from healthy individuals but from non-ischaemic DCM patients, where changes in the connective tissue architecture of the heart occur even without evident gross scar formation. The underlying disease may have influenced our results, but this also implies cECM from DCM patients still has the required biologic activity. Finally, the ECM slices we prepared are ideal for in vitro studies, but their size would need to be increased for possible therapeutic applications. Upscaling may create problems regarding the nutrient supply to cells and its consequences would have to be studied in detail.
Clinical relevance
Both cardiac surgeons and cardiologists have been performing cell therapy in failing hearts for more than 10 years, and the results have uniformly been modest. The limited efficacy is at least partially due to the artificial environment that cells face in standard culture systems. We found that human cardiac ECM reduces cell death (anoikis) and helps pluripotent stem cells to develop into cardiomyocytes, and this phenomenon may be exploited by bringing stem cells in contact with cECM during the preparation phase and/or by adding cECM to cell products when they are injected into the myocardium. Before this can be done in heart failure patients, however, clinical-grade cECM needs to be developed that meets the strict regulatory requirements for advanced therapeutic medicinal products, a process that is expected to take at least 5 years.
Conclusion
Decellularized human cardiac ECM supports viability and proliferation of murine embryonic and induced pluripotent stem cells. In comparison with other matrix preparations, cECM contact induces a gene expression pattern that seems to favour differentiation towards a cardiomyocyte-like phenotype. Therefore, cECM may help optimize myocardial regeneration and tissue engineering strategies using pluripotent stem cells. Ultimately, a hybrid scaffold consisting of a biodegradable polymer structure for initial stability and gross architecture, combined with organotypic decellularized matrix to supply appropriate biological cues may be the best solution for myocardial tissue engineering and/or in vitro expansion of cardiomyogenic cells.
APPENDIX. CONFERENCE DISCUSSION
Dr U. Stock (Frankfurt am Main, Germany): I believe we all learned the hard way that isolated stem cell injection, either surgically or by test technique, didn't fulfill our expectations regarding cardiomyocyte differentiation. So it is a very logical and elegant mess that faces any group looking at a combination of extracellular matrix and myocardial tissue for the potential to move forward into cellular matrix or myocardial differentiation into cardiomyocytes. However, when reading your manuscript I was curious about a couple of issues in your methods section. First of all, you mentioned that you used tissue either derived from patients undergoing Morrow resection or transplant and LVAD. So these are all three different groups. Morrow resection is usually used for patients with aortic stenosis with severe left ventricular hypertrophy. So you have a hypertrophy of the myocardium. And the next group is transplant candidates or LVAD candidates. These are patients, the majority having either congenital disease or ischaemic or dilated cardiomyopathy. We learned in the past that extracellular matrix is altered. It is not only the cardiomyocyte, but even the extracellular matrix that is altered, for instance, in dilated cardiomyopathy.
So the question is, have you looked at subgroups of your bio seeds on the left ventricular wall and on the left ventricular septum, as there are differences between patients with dilated cardiomyopathy, myocarditis, or even patients with normal aortic stenosis? Second, you have an impact of age on your tissue. For instance, if you know that elastogenesis is normally coming to a halt at the age of 18, so after 18 we no longer have elastogenesis in our body, even in the myocardium, so if you have younger tissue samples, this might have an impact on your study as well.
And third of all, I would like to know about your view of the future clinical application, how you would like to apply your technique. Would you like to use soluble extracellular matrix proteins, for instance, mix them with ISP cells for injection, or how do you envision the future application of your technique?
Ms Oberwallner: We had matrix from different patients. We did not separate them into different groups, because, of course, it is not easy at all to get large amounts of heart tissue. But what we did is we compared matrix from all the healthy regions with matrix from fibrotic regions after myocardial infarction. And, of course, histologically you can see a difference here. You can see in the fibrotic regions that there are almost no cells to begin with, and the collagen network is denser, and it also stays denser after decellularization. So what we tried to do is to exclude matrix from these fibrotic regions, or tissue from these fibrotic regions, and only to decellularize from more or less intact regions. The tissue itself was mostly from elderly patients, I have to say.
Regarding the clinical applications, one could imagine various things. One can decellularize the extracellular matrix to inject it, but it might also be possible to recellularize it and then to create a patch and to implant these patches as a whole, for example. But, first of all, this would have to be tested in animal studies, of course.
